Detroit To Be Quantic Dream’s Next Sony PlayStation 4 Exclusive

28 Oct 2015 | Author: | No comments yet »

A Captivating Android Finally Gets Her Game: Detroit.

The famous game developer, David Cage, today revealed that his studio Quantic Dream is developing a new title for PlayStation 4 called Detroit: Become Human.Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) has tried to make a strong comeback, responding to Enron-like fraud allegations leveled on it by a short-selling research firm, Citron.If you cast your mind back to 2012 you will remember Heavy Rain and Beyond: Two Souls developer Quantic Dream released a tech demo called Kara, about an android who didn’t want to be pulled apart.

The title should stir a lot of excitement, as Quantic Dream’s 3D graphics always push the edge of realism in its attempts to tell meaningful stories. The show they put on was worth the wait though, with multiple new announcements and more detailed looks at games that have only been briefly shown before.

We’ll cover some of the bigger reveals separately, but it seems appropriate to start with the two games that ended the conference – since both are from prominent French developers. A trailer for the game shows off the conceit; it takes place in a future Detroit where commercially-sold androids are the latest technological gadget, but human-android relations are clearly not all smiles and laughter. Canada-based Valeant, long known as a serial acquirer, lost a hefty 40% of its stock value to hit the lowest of $88.5 on October 21, after Citron’s report went public. I could make some other inferences based on my opinion of Quantic Dream’s other titles, but I don’t think fans of their games would appreciate them, so instead let’s just watch the trailer for Detroit: Become Human together and be happy and nice.

If you want to get some insight into the original tech demo that might lead to some clues as to where the actual game will go, check out Chris Baker’s 2012 story on Kara for WIRED. When the company tried to turn around the declining trend by responding to the allegations in an investors’ call this Monday, the drug-makers’ stock fell by another 5.27% to close at $110.04. We get the feeling that Cage must’ve watched the movie Ex Machina in the meantime though, and that seems to have convinced him to continue the story of Kara the robot who becomes unexpectedly self-aware.

The drug-maker has thus established an ad hoc committee to look into Citron’s allegations in detail, regarding Valeant’s business relationship with Philidor and other specialty pharmacies. We’ll be honest, we can’t stand David Cage’s work but we do have an awful lot of respect for Rayman creator Michel Ancel, who was also on hand at the conference to unveil a gameplay demo for WiLD. Unsurprisingly, he didn’t address the issue of whether he still works at Ubisoft or not, as WiLD is being developed at an independent studio called Wild Sheep.

The option was originally acquired in December 2014, to purchase Philidor for $100 million. “Philidor employees do not report to Valeant,” Valeant CEO Michael Pearson stated. Some employees currently working at Philidor Rx Services LLC revealed that they often ran into a colleague named Bijal Patel who tracked prescriptions. Interviews with doctors prescribing Valeant’s drugs and patients, and talks with former employees of both the companies, have made it apparent that these two companies do have close ties. These people also said that the secret ties of the two companies were kept hidden so as to conceal the reality that Valeant was actually using the pharmacy specifically to push its expensive drugs to patients.

Since Valeant is the only supplier of Philidor and directly consolidates Philidor’s financials in its own books, there is no way the actual sales figures can be verified until Valeant agrees to reveal them. The threshold counts relationships contributing worth 10% or above to Valeant’s revenue as material; since Philidor generates less than 7% to Valeant’s net revenue, as per 4QFY14, Philidor is immaterial for Valeant’s reporting purposes.

Even if Valeant’s revenue contribution figure for Philidor is correct, Valeant could still be hiding even more such illegal relationships with specialty pharmacies. Valeant’s business model revolves around acquiring-to-expand via hefty price hikes of the acquired drugs, slashing of talented workforce of the purchased companies, and consistently decline in research and development expenditures.

Valeant has experienced supercharged growth only via its aggressive deal-making strategy; the company has signed more than 100 deals in last seven years.

Here you can write a commentary on the recording "Detroit To Be Quantic Dream’s Next Sony PlayStation 4 Exclusive".

* Required fields
All the reviews are moderated.
Twitter-news
Our partners
Follow us
Contact us
Our contacts

dima911@gmail.com

ICQ: 423360519

About this site